Despite promising preclinical results of various therapeutic anticancer immunization strategies, these approaches may not be effective enough to eradicate tumors in cancer patients. While most animal models are based on fastgrowing transplantable tumors, malignancies in, for example, cervical cancer patients in general develop much more slowly, which may lead to immune suppression and/or immune tolerance. As a consequence, the immunomodulating signal of any therapeutic immunization regimen should be sufficiently potent to overcome this immunocompromised condition. In previous studies, we demonstrated that an experimental vaccine against human papillomavirus (HPV)-induced cervical cancer, based on Semliki Forest virus (SFV), induces robust HPV-specific cellular immune responses in mice. Now we studied whether this strategy is potent enough to also prime a cellular immune response in immune-tolerant HPV transgenic mice, in which CTL activity cannot be induced using protein or DNA vaccines. We demonstrate that, depending on the route of immunization, SFV-expressing HPV16 E6 and E7 indeed has the capacity to induce HPV16 E7-specific cytotoxic T cells in HPVtransgenic mice. Gene Therapy (2005) Since the continued production of E6 and E7 is required for the maintenance of the transformed phenotype, E6 and E7 in fact represent tumor-specific antigens in cervical carcinoma and premalignant HPV-transformed cells. As a consequence, E6 and E7 are potential targets for immunotherapeutic intervention strategies involving induction or stimulation of cytotoxic T lymphocyte (CTL) activity against HPV-transformed cells. 
Cervical cancer is the third most common cancer among women worldwide. It is caused by infection with highrisk human papillomavirus (HPV), in particular types 16, 18, 31, 33 or 45. Indeed, in over 99% of all cervical carcinomas, DNA derived from these HPV types is detectable. 1 High-risk HPVs have the capacity to transform cervical epithelial cells by integrating the open reading frames encoding the viral early proteins E6 and E7 into the host cell genome. This integration may lead to constitutive overexpression of E6 and E7, mediating transformation of the cells to a malignant phenotype.
Since the continued production of E6 and E7 is required for the maintenance of the transformed phenotype, E6 and E7 in fact represent tumor-specific antigens in cervical carcinoma and premalignant HPV-transformed cells. As a consequence, E6 and E7 are potential targets for immunotherapeutic intervention strategies involving induction or stimulation of cytotoxic T lymphocyte (CTL) activity against HPV-transformed cells. 3 It is likely that HPV-specific CTLs play an important role in the immunological control of tumor development after HPV infection. 3 Indeed, while the majority of sexually active women become infected with HPV, only a minority develops premalignant cervical lesions or cervical cancer. 4 In these patients, as expected, HPVspecific CTL activity is generally low, 5, 6 suggesting that they have mounted a certain degree of immunological tolerance or ignorance for the HPV-derived antigens. It is possible that this tolerance arises peripherally at the level of the epithelial keratinocytes, the target cells for HPV. These keratinocytes lack costimulatory molecules such that presentation of viral antigens in the context of MHC class I molecules may result in the induction of anergy in relevant T cells, thus causing immunological tolerance. Recently, Steinman and Nussenzweig 7 proposed that peripheral tolerance can also be induced by immature dendritic cells (DCs), which silence the T-cell repertoire to self and environmental antigens captured in the steady state, that is, in the absence of an acute infection or inflammation. This induction of tolerance by immature DCs would be mediated by peripheral T-cell deletion or by the induction of regulatory T cells. Immunological tolerance for chronic or persistent viral pathogens, such as HPV, could develop in a similar manner. Irrespective of its precise origin, the 'putative' immunological tolerance for HPV antigens in patients with cervical carcinoma or premalignant cervical disease puts high demands on potential immunotherapeutic strategies, since such approaches need to break or overcome this tolerance in order to be effective.
In previous studies, [8] [9] [10] we have demonstrated that immunization of mice with recombinant Semliki Forest virus (SFV) expressing a fusion protein of HPV16 E6 and E7 (SFV-enhE6,7) not only induces strong and longlasting CTL responses but also effectively eradicates established tumors of HPV-transformed cells. In the present study, we used K10HPV16-E6/E7 transgenic (Tg) mice, which constitutively express HPV16 E6 and E7 under the control of the keratin 10 promoter in the suprabasal layers of the epidermis. Upon immunization with E7 protein, these mice produce anti-E7 antibodies but no E7-specific CTLs. 11, 12 The antibody response has been shown to be comparable to that of their nontransgenic littermates, demonstrating that E7-specific B cells as well as T helper cells are not deleted during development. By contrast, the CTL tolerance is extremely strong, since attempts to break it with protein or DNA vaccination have thus far been unsuccessful. 12, 13 The inability of K10HPV16-E6/E7 Tg mice to mount an E7-specific CTL response is not due to a general CTL unresponsiveness, because these mice are capable of generating specific CTL activity against, for example, ovalbumin. 12 These results suggest that, similar to the HPV-transgenic murine model in which HPV16-E6/E7 is expressed from the K14 promotor, expression from the K10 promotor results in 'split' tolerance, in which antigen-specific CTL responses are strongly suppressed but the antibody and T helper responses remain unaffected.
14 In the present study, we demonstrate that immunization of K10HPV16-E6/E7 Tg mice with SFVenhE6,7 does induce CTL activity. Although the mechanism and kinetics of tolerance in this mouse model certainly differ from that in the human clinical situation, these studies do demonstrate the potency of immunization with the SFV-enhE6,7 vector.
Spleen cells isolated from wild-type ( Figure 1a ) as well as Tg mice (Figure 1b ), immunized with 10 7 i.u. SFVenhE6,7, displayed a high level of cytolysis against C3 target cells (squares), while no significant HPV-specific CTL activity was observed in the SFV-LacZ and PBS control groups (closed and open circles, respectively). Although, as expected, the cytolysis in wild-type mice was higher than in Tg mice, this result demonstrates that immunization of K10HPV16-E6/E7 Tg mice with SFVenhE6,7 can induce E7-specific CTLs in these animals.
Next, using interferon-g (IFN-g) Elispot analysis, 18 we determined the number of HPV-specific IFN-g-secreting T cells after 7 days of in vitro restimulation with 13-2 cells. As shown in Figure 2 , immunization of wild-type (open circles) and Tg mice (solid circles) with SFV-enhE6,7 elicited T cells specific for E7 [49] [50] [51] [52] [53] [54] [55] [56] [57] . The background level of IFN-g-secreting cells in the PBS and SFV-LacZ control groups is not E7-specific but due to the 7-day culture in the presence of IL-2. In these control groups, the numbers of spots in wells stimulated with or without E7 protein were the same. Again similar to the bulk CTL analysis, the response in wild-type mice was higher than that in Tg mice. Assuming an equal doubling rate of pCTL from wild-type and Tg T cells during in vitro restimulation, the Elispot results suggest that the pCTL frequency induced in wild-type mice is approximately 10-fold higher than that in Tg mice. The relatively low level of pCTLs induced in Tg mice cannot be determined by direct ex vivo Elispot or tetramer analysis as these levels range around the detection limit of these methods (not shown). In contrast, pCTL levels in wild-type mice can be determined directly ex vivo, both by Elispot and tetramer analysis. 8 Michel et al 13 recently demonstrated that immunization of K10HPV16-E6/E7 Tg mice with VP22-E7 1-60 DNA was unable to overcome the E7-specific tolerance. Since the experimental conditions of the CTL assay used by these authors differed from the conditions in our experiments, we directly compared the efficacy of the DNA immunization with SFV-enhE6,7 immunization in our model. A strong HPV-specific CTL activity was induced in wild-type mice upon immunization with VP22-E7 1-60 DNA (Figure 3 , open circles). In contrast, no HPV-specific CTL activity was observed in the Tg mice immunized with the DNA (Figure 3 , closed circles), while immunization with SFV-enhE6,7 induced a significant HPV-specific CTL response in these mice ( Figure 3, closed squares) .
In wild-type mice, intravenous (i.v.) or intramuscular (i.m.) injection of recombinant SFV results in higher levels of CTL activity compared to subcutaneous (s.c.) or intraperitoneal (i.p.) injection. 10, 19 To examine whether this also holds true in the K10HPV16-E6/E7 model, Tg mice were immunized via three different routes (s.c., i.m. or i.v.) with 10 7 i.u. SFV-enhE6,7. As shown in Figure 4 , s.c. immunization induced a higher level of CTL activity 11 Expression of E6 and E7 was confirmed by PCR of DNA obtained from tail specimens. No difference in E6 and E7 expression was observed between homozygous and heterozygous F1 mice. In addition, no differences in CTL induction were observed between these mice (not shown). The production and purification of recombinant SFVenhE6,7 and SFV-LacZ was performed as described previously. The results presented in this report illustrate the exquisite potency of the SFV vector system as a means to induce CTL activity. While conventional DNA-and protein-based vaccines were unable to induce CTLs in K10HPV16-E6E7 Tg mice, 12,13 SFV-enhE6,7 did efficiently prime CTL activity in these mice.
HPVs have evolved such that infected cells and (pre)malignant cells are not recognized effectively by the immune system. For example, expression of HPV E6 and E7 protein prevents the immunoregulatory effects of IFN-a-and IFN-b-mediated antiviral responses. 20 It is furthermore observed that women with cervical cancer develop poor levels of E7-specific CTLs in response to the developing tumor 5, 6 or to an E7 vaccine. 21 This poor cellular immune response may be caused by the expression of E7 in epithelial cells lacking costimulation, which may lead not only to immunosuppression but also to immunological tolerance. Scavenge of E7-expressing cells by Langerhans cells (LCs) or DCs without costimulation would thus prevent DC maturation. These immature DCs will transmit a tolerogenic rather than stimulatory signal to T cells. This and several other mechanisms of HPV-mediated immune escape have been recently reviewed by Tindle. 22 Considering these immune evasion strategies of HPV, Tindle proposes that immunization with any form of E7 will have to provide the so-called 'danger' signals 23 that turn immature, tolerizing DCs into mature, activating DCs. The recombinant SFV system would appear to meet these criteria in that both the innate and the adaptive immune systems are activated. Infection of cells with SFV results in the formation of dsRNA intermediates 24 that are known for their immunopotentiating capacity. 25 dsRNAs can be recognized by innate immune receptors, such as Toll-like receptor 3, and trigger production of IFN type I. In addition, dsRNAs induce activation and maturation of DCs. 26 Uptake of apoptotic cells transfected with recombinant SFV will thus not only provide the specific antigen but also provide the required danger signal. , in the tibialis anterior, with 100 mg VP22-E7 1-60 DNA. 13 The muscles of the mice were pretreated with 50 ml of 10 mM cardiotoxin 7 days prior to DNA injection. As a positive control, Tg mice were immunized s.c. and boosted twice with 10 7 i.u. SFV-enhE6,7 (n ¼ 2; closed squares). At 10 days after i.m. injection of VP22-E7 1-60 DNA and 7 days after the last booster with SFV-enhE6,7, mice were killed and CTL activity was determined as described above. The levels of cytolysis at different effector-to-target ratios are shown. Recombinant SFV induces HPV E6/E7-specific CTLs in E6/E7-transgenic mice A Riezebos-Brilman et al
The observation that in wild-type mice i.v. and i.m. immunization results in higher CTL responses than s.c. or i.p. immunization, whereas in K10HPV16-E6E7 Tg mice the s.c. route seems superior, could be explained by the following observations. As described above, K10HPV16-E6E7 Tg mice express E6 and E7 in keratinocytes. Fausch et al 27 recently demonstrated that human LCs, which reside in the epidermis of the skin or in epithelia of mucosal tissues, bind and internalize HPV virus-like particles but do not upregulate markers nor initiate an HPV-specific immune response. Thus, LCs cells can be considered to be (co)responsible for the induction and maintenance of HPV tolerance. Breaking this tolerance could best be achieved by specifically targeting danger signals to tolerogenic LCs. As suggested above, immunization with recombinant SFV provides the danger signal that is needed to activate and mature LCs. Indeed, Johnston et al 28 demonstrated that in vivo epidermal infection with SFV significantly increases the expression of MHC II, CD54 and CD80 on LCs. Thus, during an epidermal viral (SFV) infection, local LCs mature to a phenotype resembling that of lymphoid DCs. One could therefore speculate that s.c. immunization of the Tg mice with recombinant SFV used in this study might result in maturation and activation of skin LCs and disruption of immune tolerance. Upon i.v. or i.m. injection, SFV-infected cells are not likely to reach LCs.
Apart from the potent immune-stimulatory effect, infection of cells with replication-incompetent recombinant SFV is highly efficient and, in addition, it is safe. Infection of cells does not proceed beyond a single round and the infected cells die by apoptosis. 29 The transient nature of infection with recombinant SFV thus provides an important safety advantage when considering using SFV as a vaccine in humans.
In summary, we have demonstrated that immunization with recombinant SFV expressing a fusion protein of HPV16 E6 and E7 induces HPV-specific CTL activity in a very stringent HPV tolerogenic mouse model. Considering the effect of the route of immunization, we hypothesize that the ability of recombinant SFV to overcome immunological tolerance in this model is due to its high efficiency and mediated by the activation and maturation of tolerogenic LCs.
